Update on mechanical circulatory support in heart failure

Heart

Volumn 98, Issue 8, 2012, Pages 663-669

  Pepper, John R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL HEART; ASSISTED CIRCULATION; ASSISTIVE TECHNOLOGY DEVICE; BIVENTRICULAR ASSIST DEVICE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DEVICE INFECTION; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HUMAN; INTERMETHOD COMPARISON; LEFT VENTRICULAR ASSIST DEVICE; LONG TERM CARE; NONHUMAN; PATIENT SAFETY; PATIENT SELECTION; PLEURA EFFUSION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PULSATILE FLOW; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

HEART FAILURE; HEART, ARTIFICIAL; HEART-ASSIST DEVICES; HUMANS; PATIENT SELECTION; POSTOPERATIVE CARE; PROSTHESIS IMPLANTATION; TREATMENT OUTCOME;

EID: 84860113083     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-300735     Document Type: Review

References (15)

1. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001;345:1435-43. This is the classic study of long term untethered LVAD support in extremely sick patients.
2. Leitz K, Long JW, Kafoury AG. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007;116:497-505. Many of the units contributing patients to the original REMATCH study were inexperienced. This study shows the benefit of gaining experience in treating these very challenging patients. (Pubitemid 47450258)
3. Hunt SA. Mechanical circulatory support: new data, old problems. Circulation 2007;116:461-2. An excellent review by an international authority. (Pubitemid 47454478)
4. Rogers JG, Butler J, Lansman SL. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 2007;50:741-7. This destination therapy study illustrates the significant haematological problems which arise in the management of these patients. (Pubitemid 47239315)
5. Radovancevic B, VrtovecdeKort B, deKort E. End-organ function in patients on long-term circulatory support with continuous or pulsatile flow assist devices. J Heart Lung Transplant 2007;26:815-18. This study highlights the contrast between pulsatile and non-pulsatile devices, and indicates the level of safety. (Pubitemid 47199072)
6. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361:2241-51. This paper brings the REMATCH study into the current era by the use of a rotary pump and has set the stage for life-long VAD treatment as an alternative to heart transplantation.
7. Birks EJ, Hall JL, Barton PJ. Gene profiling changes in cytoskeletal proteins during clinical recovery after left ventricular-assist device support. Circulation 2005;112:157-64. This gives an intriguing insight into some of the molecular pathways involved in ventricular remodelling.
8. Matthews JC, Koelling TM, Pagani FD. The right ventricular failure risk score, a preoperative tool for assessing the risk of right ventricular failure in left ventricular assist candidates. J Am Coll Cardiol 2008;51:2163-72. The right ventricle is often overlooked in the assessment of left ventricular failure. This study highlights the importance of optimising right ventricular function as much as possible before insertion of an LVAD. (Pubitemid 351713685)
9. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006;355:1873-84. This is one of the most successful reports of recovery of patients with end-stage heart failure. (Pubitemid 44664645)
10. Birks E, George RS, Hedger M, et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy. A prospective study. Circulation 2011;123:381-90. This study reports on a high success rate of recovery in end-stage heart failure using a non-pulsatile rotary pump.
11. Copeland JG, Smith RG, Arabia FA. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004;351:859-67. The total artificial heart is again in the news, but this is the group who have, almost alone, pioneered this device. Currently it is used as a bridge to transplant only. (Pubitemid 39099324)
12. Klotz S, Barbone A, Reiken S. Left ventricular assist device support normalises left and right ventricular beta-adrenergic pathway properties. J Am Coll Cardiol 2005;45:668-76. (Pubitemid 40278964)
13. Clegg AJ, Scott DA, Loveman E, et al. Clinical and cost-effectiveness of left ventricular assist devices as a bridge to heart transplantation for people with end-stage heart failure: a systematic review and economic evaluation. Eur Heart J 2006;27:2929-38. There is very little information on cost effectiveness or cost benefit in the use of VADs. This is one of the few studies and has interesting conclusions. (Pubitemid 44950434)
14. Hunt SA, Baker DW, Chin MH. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and management of heart Failure). J Am Coll Cardiol 2001;38:2101-13.
15. Birks EJ. The comparative use of ventricular assist devices: differences between Europe and the United states. Texas Heart Inst J 2010;37:565-7.